Home' Australian Pharmacist : Australian Pharmacist October 2015 Contents Australian Pharmacist October 2015 I ©Pharmaceutical Society of Australia Ltd.
Vyvanse (lisdexamfetamine dimesilate),
a once-daily treatment for attention
deficit hyperactivity disorder (ADHD),
was listed on the Pharmaceutical
Benefits Scheme (PBS) on 1 September.
According to Shire, it is the first time a
treatment for ADHD has been added
to the PBS in over five years, providing
healthcare professionals (HCPs) with an
alternate option to help control the core
symptoms of ADHD.
Vyvanse belongs to a class of
medications known as stimulants – it is
the only prodrug stimulant licensed for
the treatment of ADHD in Australia.
Using prodrug technology, the inactive
molecule is gradually converted in the
blood, making the active part of the
medicine, dexamphetamine, available
in the body over a period of time.
Vyvanse is a long-acting medication
and will be available on the PBS
for patients requiring continuous
coverage for over 12 hours.It has a
well-established safety profile. Adverse
events observed with Vyvanse treatment
are broadly consistent with the known
side effects associated with other
stimulant medications. Vyvanse offers
once-daily oral dosing that can be
taken as a whole capsule or the entire
capsule contents dissolved in water and
1. Vyvanse Approved Product Information. At: www.
The first in a new class of biologic
medicine that acts to interrupt the
inflammatory cycle and help clear the
skin of patients with moderate-to-severe
was added to the
Pharmaceutical Benefits Scheme on 1
September. The PBS listing of Cosentyx
(secukinumab) – the first interleukin-17A
– for patients with severe
chronic plaque psoriasis refractory to
treatment with non-biologic DMARD
therapy follows the publication of
head-to-head trial data in moderate-
to-severe psoriasis patients that found
the injectable therapy (300mg daily) is
superior to Stelara (ustekinumab) (79%
vs 57.6% - PASI 90 response at week
Cosentyx works by stopping the action
of interleukin-17A (IL-17A), a protein
that is central to the development of
inflammatory diseases, to interrupt the
inflammatory cycle of psoriasis.
The Phase III ERASURE and FIXTURE
studies showed Cosentyx 300mg
achieved almost clear skin (PASI 90) in
69.8% and 72.4% of patients respectively
after 16 weeks of treatment.
(PASI 100) was achieved in 41.6% and
36.8% of patients treated with Cosentyx
at week 16 in the respective trials.
1. TGA Approved Product Information for Cosentyx
(Secukinumab). Novartis Pharmaceuticals Australia, Jan
2. ARTG At: www.tga.gov.au/artg/artg-id-218799. Accessed
3. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior
to ustekinumab in clearing skin of subjects with moderate
to severe plaque psoriasis: 16 week results from the CLEAR
study. J Am Acad Dermatol 2015; June 16. At: http://dx.doi.
org/10.1016/j.jaad.2015.05.013 (Accessed: 18 Jun 2015).
Maternity and baby skin
Mater Mothers’ Hospitals has been
granted official Australian Made and
Owned certification for its maternity and
baby skin care products.
Produced in South East Queensland,
Mater Baby Moisturiser, Baby Wash,
Nappy Balm and Body Balm for
pregnancy will now carry the Australian
Made logo. According to Roy Morgan
Research, the Australian Made logo
enjoys a 98.8% recognition level among
Mater Mothers’ Hospitals Director
of Women’s Health Services,
Maree Reynolds said she was excited to
see the Mater maternity and baby skin
care products achieve the Australian
‘ We are committed to ensuring that our
products are not only the best quality
for mothers and babies, but also that
the products are made locally using
trustworthy ingredients. We are very
proud that our maternity and baby
skin care products will now wear the
Australian made logo.’ she said.
Mater skin care products are designed
for expectant mums, new mums and
their delicate newborn baby’s skin,
offering a unique high-quality range
that is safe, ethical and affordable.
Proceeds from the Mater maternity
and baby care product range supports
Mater Little Miracles to fund important
research projects that will give babies
throughout Australia, the best possible
start in life.
Links Archive Australian Pharmacist September 2015 Australian Pharmacist November 2015 Navigation Previous Page Next Page